Company
Lobe Sciences Ltd
OTCMKTS:LOBEF
Lobe Sciences is a biopharmaceutical company focused on developing patient-friendly, practical psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using sub-hallucinatory doses of psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness. Each of our New Chemical Entities, L-130 and L-131, are being developed to address unmet medical needs in neurological therapeutic applications.
33 stories
Lobe Sciences completes production of psilocin analogues for use in clinical trials
“Our manufacturing partner has produced sufficient quantities of L-130 to dose subjects and patients in our first two Phase 1 programs," said Lobe Sciences CEO Phillip J Young
Lobe Sciences recruits biotech and pharma leader to its board
"Baxter brings to Lobe both a broad, practical experience with a variety of public and private pharmaceutical companies," said CEO Philip J Young
Lobe Sciences announces expansion of patent portfolio with international filings
"This important step is a significant demonstration of our capabilities, particularly as we expand our footprint globally through conducting controlled clinical trials with our patent-pending compound and expanding our patent portfolio inte
Lobe Sciences incorporates Australian subsidiary to facilitate clinical trials for psilocin analogues with partner iNGENū
Per the Australian Federal Government’s Research & Development tax incentive program, Lobe will receive rebates for up to 43.5% on eligible expenditures for research and development conducted in Australia, the company said
Lobe Sciences secures $1.3M private placement to fund advancement of its brain trauma-treating psilocin analogs
Proceeds from the offering are expected to be used for manufacturing and regulatory activities necessary to support initial human clinical trials with novel psilocin analogs L-130 and L-131
Lobe Sciences inks US$1.5M investment agreement to fund Australian clinical trials
“The opportunity to advance our proprietary psilocin compounds in multiple human trials puts Lobe in a leading position within the psychedelic biotech marketplace,” Lobe Sciences CEO Philip Young said
Lobe Sciences is developing innovative and accessible psychedelic-inspired medicines for severe anxiety, traumatic brain injury, and more
Lobe Sciences is focused on developing and stabilizing psilocin, the active metabolite of the psychedelic compound psilocybin, for a range of indications including severe anxiety and a yet-to-be-announced rare disease
Lobe Sciences enters into exclusive agreement with contract research organization iNGENū to conduct clinical trials in Australia
“We evaluated CROs in multiple geographies and chose iNGENū as their core values match ours and our commitment to discovering transformational therapies for multiple central nervous system diseases and trauma,” said Lobe Sciences CEO Philip
Lobe Sciences files patent for preparation of stable psilocin prodrugs and analogues
"Our patent portfolio now consists of multiple patent filings for the use and delivery of psilocybin, psilocin analogues and N-Acetyl Cysteine (NAC) as well as a new patent that covers the uses and preparation of multiple proprietary stable
Lobe Sciences updates investors on its regulatory and clinical development plans for its novel synthetic psilocin analogues L-130 and L-131
“Our initial focus for our clinical program is to treat neurologic disorders, such as severe anxiety and we are in the final stages of selecting a contract research organization to support these studies," said Lobe Sciences CEO Philip Young